Background
==========

As society progresses, work rhythm speeds up, and living and eating habits change, younger women are at increased risk of different types of endometrial lesions \[[@b1-medscimonit-22-4786],[@b2-medscimonit-22-4786]\]. The most common types of endometrial lesions are endometrial polyps, uterine adenomyosis, and malignant endometrial adenocarcinoma \[[@b3-medscimonit-22-4786],[@b4-medscimonit-22-4786]\]. The incidence of endometrial polyps in women reached 25%, with the main clinical symptoms being large menstrual flow, intermenstruum bleeding, menstrual abnormalities, and infertility. Endometrial polyps in the perimenopausal or postmenopausal period easily induce cancer \[[@b5-medscimonit-22-4786]\]. As a common type of endometrial disease, endometrial polyps frequently occur in women, with easy relapse that seriously affects life quality and fertility \[[@b6-medscimonit-22-4786]\]. In uterine adenomyosis, uterine glands or uterine stromal endometrial tissue enters the myometrium, inducing pathological changes such as myometrium nodular changes, especially uterine adenomyoma, which is common in young women \[[@b7-medscimonit-22-4786]\]. As uterine adenomyosis is often accompanied with compensatory hyperplasia and hypertrophy, and occurs in fertile women, it often causes severe symptoms, mainly increased menstrual volume, abnormal menstrual period, severe abdominal pain, and infertility \[[@b8-medscimonit-22-4786]\]. Endometrial cancer is among the 3 most common malignant tumors in the female reproductive system. Endometrial adenocarcinoma is the most common type, with increased incidence and a trend toward affecting younger women \[[@b9-medscimonit-22-4786],[@b10-medscimonit-22-4786]\].

Pro-apoptotic gene p53, which is a tumor suppressor gene, plays an important role in regulating cell apoptosis. P53 accumulated in the nucleus, leading to DNA damage by binding with the cell division control site \[[@b11-medscimonit-22-4786],[@b12-medscimonit-22-4786]\]. Murine double mimute 2 (MDM2) was first found from the double mimute in transformation mice. It was further confirmed to be expressed in various tissues and organs. MDM2 overexpression in nude mice can lead to excessive cell proliferation and tumor formation. Thus, MDM2 may promote tumor occurrence and development by promoting tumor cell proliferation and growth. It is an oncogene that can promote tumor occurrence and development \[[@b13-medscimonit-22-4786],[@b14-medscimonit-22-4786]\]. MDM2 can play a role in 2 ways, as its translation product can bind with p53 protein, thus inhibiting pP53 transcription activity. It further degrades wild-type p53 protein, and plays a stabilizing role in mutant P53 protein \[[@b15-medscimonit-22-4786]\]. MDM2 also can play an oncogene role independent of p53 method, as a promotor gene. It can promote cell cycle from G1 to S phase, or suppress oncogenes through zinc finger structures. It also can stimulate cell proliferation by binding with Rb-related E2F \[[@b16-medscimonit-22-4786],[@b17-medscimonit-22-4786]\]. Differences in P53 and MDM2 expression in various endometrial lesions have not been reported. This study aimed to analyze p53 and MDM2 mRNA and protein expression in normal endometrium, endometrial polyps, uterine adenomyosis, and endometrial adenocarcinoma tissues, to provide a reference for diagnosis and treatment of endometrial lesions in clinical practice.

Material and Methods
====================

Study subject selection and specimen collection
-----------------------------------------------

A total of 71 patients with different types of endometrial lesions diagnosed between January 2014 and June 2015 in Chengdu Military General Hospital were selected and assigned to 4 groups. The control group consisted of 15 patients who underwent hysterectomy because of uterine prolapse, uterine fibroids, or ovarian benign tumor. The endometrial polyps group (polyps group) consisted of 20 patients diagnosed as having single or aggregated multiple endometrial polyps by pathology who underwent hysteroscopic operations. The uterine adenomyosis group (adenomyosis group) consisted of 17 uterine adenomyosis patients diagnosed by pathology who underwent hysterectomy. The endometrial adenocarcinoma group (adenocarcinoma group) consisted of 19 endometrial adenocarcinoma patients in stage I--III who underwent hysterectomy. The patients enrolled were ages 37--69 (58.6±10.2) years. One-way ANOVA analysis revealed that general characteristics of patients in the 4 groups showed no statistically significant differences ([Table 1](#t1-medscimonit-22-4786){ref-type="table"}). No patients received radiotherapy, chemotherapy, or hormone therapy before surgery. No patients received antibiotic therapy or intrauterine device. Patients whose cases were complicated with other reproductive system disease, severe organ failure, other malignant tumors, or severe complications were excluded. Intraoperative endometrial specimens were collected and preserved at −80°C until needed.

The study protocol was approved by the Research Ethics Committee of Chengdu Military General Hospital, and all patients gave their informed consent before study commencement.

Main materials and instruments
------------------------------

TRIzol reagent was from Invitrogen. Polyvinylidene difluoride (PVDF) membrane was from Pall Life Sciences. Western blot-related chemical reagents were bought from Beyotime. ECL reagent was from Amersham Biosciences. Mouse antihuman p53 primary antibody, mouse antihuman MDM2 primary antibody, and goat anti-mouse horseradish peroxidase (HRP)-tagged IgG secondary antibody were from Cell Signaling. The SABC immunohistochemical staining kit was purchased from Boster Bio-engineering, Ltd. (Wuhan, China). The RNA extraction kit and reverse transcription kit were from Invitrogen. DNA amplifier was from PE Gene Amp PCR System2400. Other common reagents were purchased from Sangon.

Real-time polymerase chain reaction (PCR)
-----------------------------------------

Total RNA was extracted from endometrial tissue using TRIzol after liquid nitrogen grinding, and reverse transcribed to cDNA according to the manual. The primers used in the experiment were designed by Primer 6.0 and synthesized by Invitrogen ([Table 2](#t2-medscimonit-22-4786){ref-type="table"}). Real-time PCR consisted of 55°C for 1 min, followed by 35 cycles of 92°C for 30 s, 58°C for 45 s, and 72°C for 35 s. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was selected as the internal reference. Relative gene expression was semiquantitatively analyzed by 2^−ΔCt^ method.

Western blot
------------

Endometrial tissues were treated by radioimmunoprecipitation assay (RIPA) solution for 15\~30 min. Then the cells were ultrasonicated 4 times at 5 s and centrifuged at 4 °C and 10 000×g for 15 min. The supernatant was stored at −20°C. The protein was separated by 10% SDS-PAGE and transferred to a PVDF membrane. After blocking by 5% skim milk for 2 h, the membrane was incubated in primary antibody (1:1000) at 4°C overnight. Next, the membrane was further incubated in secondary antibody (1: 2000) at room temperature for 30 min after washing with phosphate balanced saline with Tween 20 (PBST). Finally, the chemiluminescent agent was added to membrane for 1 min and developed. Protein image processing system software and Quantity One software were used for scanning and calculation. All experiments were repeated 4 times (n=4).

Immunohistochemical staining
----------------------------

Immunohistochemical staining was performed using a SABC kit according to manufacturer's instructions. Briefly, tissue slices were incubated with 3% H~2~O~2~ at room temperature and blocked with 10% goat serum. Then the slices were incubated with antibody against p53 (1 in 1000 dilution) or MDM2 (1 in 500 dilution) for 1 h at 37°C and then washed 3 times with PBS. After that, biotin-labelled goat anti-mouse secondary antibody was added. Color was developed with 3, 3′-diaminobenzidine. Positivity (+) was defined as less than 50% positive cells and Positivity (++) was defined as more than 50% positive cells.

Statistical analysis
--------------------

SPSS19.0 was used for data analysis. Measurement data are presented as mean ± standard deviation (χ̄±S). One-way ANOVA was used to compare the differences of age and expression of p53 or MDM2 within different groups, and Spearman correlation analysis was used for to assess the correlation of p53 expression with MDM2. P\<0.05 was considered as statistical significance.

Results
=======

P53 mRNA expression in different types of endometrial lesions
-------------------------------------------------------------

Real-time PCR was used to detect p53 mRNA expression in different types of endometrial lesions. The results showed that p53 mRNA was expressed in the control group and it increased in the adenomyosis group, but the difference lacked statistical significance (P\>0.05). The polyps group and adenocarcinoma group both showed significantly overexpressed p53 mRNA compared with controls (P\<0.05). Its level in the adenocarcinoma group was obviously higher compared with the polyps group (P\<0.05) ([Figure 1](#f1-medscimonit-22-4786){ref-type="fig"}).

P53 protein expression in different types of endometrial lesions
----------------------------------------------------------------

Western blot was used to test p53 protein expression in different types of endometrial lesions. Similar to p53 mRNA expression, p53 protein was expressed in the control group and it was elevated in the adenomyosis group but the difference lacked statistical significance (P\>0.05). The polyps group and adenocarcinoma group both presented markedly increased p53 protein expression compared with controls (P\<0.05). Its level in the adenocarcinoma group was significantly higher compared with the polyps group (P\<0.05) ([Figures 2](#f2-medscimonit-22-4786){ref-type="fig"}, [3](#f3-medscimonit-22-4786){ref-type="fig"}). Consistent with these results, immunohistochemical staining analysis displayed the same patterns of p53 expression, with higher expression in the polyps group and adenocarcinoma group ([Figure 4](#f4-medscimonit-22-4786){ref-type="fig"}, [Table 3](#t3-medscimonit-22-4786){ref-type="table"}).

MDM2 mRNA expression in different types of endometrial lesions
--------------------------------------------------------------

Real-time PCR was performed to detect MDM2 mRNA expression in different types of endometrial lesions. The results showed that MDM2 mRNA was expressed in the control group and was elevated in the adenomyosis group, but the difference lacked statistical significance (P\>0.05). The polyps group and adenocarcinoma group both showed significantly enhanced MDM2 mRNA compared with controls (P\<0.05). Its level in the adenocarcinoma group was obviously higher than that in the polyps group (P\<0.05) ([Figure 5](#f5-medscimonit-22-4786){ref-type="fig"}).

MDM2 protein expression in different types of endometrial lesions
-----------------------------------------------------------------

Western blot analysis was further used to test MDM2 protein expression in different types of endometrial lesions. Similar to MDM2 mRNA expression, MDM2 protein was expressed in the control group and it was elevated in the adenomyosis group, but the difference lacked statistical significance (P\>0.05). The polyps group and adenocarcinoma group both presented markedly increased MDM2 protein expression compared with controls (P\<0.05). Its level in the adenocarcinoma group was obviously higher compared with the polyps group (P\<0.05) ([Figures 6](#f6-medscimonit-22-4786){ref-type="fig"}, [7](#f7-medscimonit-22-4786){ref-type="fig"}). Consistent with these results, immunohistochemical staining analysis also displayed the same patterns of MDM2 expression, with higher expression in the polyps group and adenocarcinoma group ([Figure 8](#f8-medscimonit-22-4786){ref-type="fig"}, [Table 3](#t3-medscimonit-22-4786){ref-type="table"}).

Analysis of the correlation between MDM2 and p53
------------------------------------------------

The relationships between MDM2 and p53 mRNA and protein level with different types of endometrial lesions were analyzed. The results showed that MDM2 and p53 mRNA and protein showed positive correlations in endometrial polyps, uterine adenomyosis, and endometrial adenocarcinoma (P\<0.05) ([Table 4](#t4-medscimonit-22-4786){ref-type="table"}).

Correlation analysis of expression of p53 or MDM2 with clinical staging of endometrial adenocarcinoma
-----------------------------------------------------------------------------------------------------

Immunohistochemical staining was performed to measure the expression level of p53 and MDM2, and then we analyzed the correlation of expression of p53 and MDM2 with clinical staging of endometrial adenocarcinoma. As seen in [Table 5](#t5-medscimonit-22-4786){ref-type="table"}, significantly higher expression of p53 or MDM2 was observed in patients with stage III compared to those in patients with stage II or I. Higher expression was also observed in patients with stage II than in patients with stage I, suggesting that expression of p53 or MDM2 might be associated with the clinical staging of endometrial adenocarcinoma.

Discussion
==========

To date, the p53 gene shows the closest relationship with human tumors. It is involved in regulating cell cycle, cell growth, apoptosis, and cell division. Tumor suppressor gene p53 is a transcription factor that can directly or indirectly control the cell cycle genes or apoptosis-related gene expression, and is involved in the apoptosis-related death receptor pathway and mitochondrial pathway \[[@b18-medscimonit-22-4786],[@b19-medscimonit-22-4786]\]. Wild-type p53 protein plays a negative role in regulating cell growth. P53 mutation or abnormal expression is an important mechanism of inducing tumors \[[@b20-medscimonit-22-4786]\]. P53 gene mutation may lead to loss of negative regulation, resulting in abnormal cell proliferation and canceration. This study analyzed p53 mRNA and protein, which are expressed in several common types of endometrial lesions. The results confirmed that p53 mRNA and protein levels in uterine adenomyosis were similar to those in controls. Its expression was significantly elevated in the endometrial polyps group and the endometrial adenocarcinoma group, especially in endometrial adenocarcinoma. Research showed that p53 gene and protein have important roles in the process of endometrial carcinoma. P53 gene activation and increased protein expression can induce abnormal cell proliferation. Its elevation can be seen in proliferative diseases, such as endometrial polyps and cancer. P53 gene mutation and abnormal protein expression often occur in the advanced stage of endometrial adenocarcinoma, and can assist diagnosing the degree of malignancy of endometrial cancer \[[@b15-medscimonit-22-4786],[@b21-medscimonit-22-4786]\].

The zinc finger structure in MDM2 can mediate protein interaction and the combination of DNA and RNA. It participates in regulating cell cycle and promoting cell proliferation, thus facilitating tumor growth \[[@b22-medscimonit-22-4786],[@b23-medscimonit-22-4786]\]. However, little is known about MDM2 expression in various endometrial lesions, including uterine adenomyosis, endometrial polyps, and endometrial carcinoma. This study confirmed that MDM2 mRNA and protein expression showed no statistically significant differences between uterine adenomyosis and normal endometrium. Its level obviously increased in endometrial polyps and endometrial adenocarcinoma, particularly in the latter. Furthermore, it had a positive correlation with p53 mRNA and protein expression. The results revealed that p53 and MDM2 were closely related to occurrence and development of endometrial lesions.

Conclusions
===========

p53 and MDM2 mRNA and protein expressions were clearly elevated in endometrial polyps and endometrial adenocarcinoma. In addition, expressions of p53 and MDM2 were correlated with clinical staging of endometrial adenocarcinoma. P53 and MDM2 can promote cancer occurrence and development, and can be used to assist in diagnosis and providing a reference for treatment.
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###### 

General information comparison.

  Index             Control     Polyps group   Adenomyosis group   Adenocarcinoma group
  ----------------- ----------- -------------- ------------------- ----------------------
  Cases (n)         15          20             17                  19
  Mean age (year)   58.1±11.8   59.6±10.3      58.7±12.7           57.9±13.1

###### 

Primer sequence.

  Gene    Forward 5′-3′          Reverse 5′-3′
  ------- ---------------------- -------------------------
  GADPH   ACCAGGTATCTGCTGGTTG    TAACCATGATGTCAGCGTGGT
  p53     GTGACCTCAGTGACCTTATG   GTTCTTCCGCTCAACTCTTATCT
  MDM2    ATGCTTCATGATGCCGACT    TTGTCAACTCTTATCCTTC

###### 

Expression of p53 and MDM2 measured by immmunohistochemical staining.

  Group            N    p53   MDM2                                                                         
  ---------------- ---- ----- ------ ----------------------------------------------------------- ---- ---- -----------------------------------------------------------
  Control          15   15    0      0                                                           15   0    0
  Adenomyosis      17   17    0      0                                                           12   5    29.4
  Polyps           20   12    8      40                                                          10   10   50
  Adenocarcinoma   19   7     12     63.15[\*](#tfn1-medscimonit-22-4786){ref-type="table-fn"}   5    14   73.68[\*](#tfn1-medscimonit-22-4786){ref-type="table-fn"}

*P*\<0.05.

###### 

Correlation analysis between MDM2 and p53.

  -------------------------------------------------------------------------------------------------------------------------------
  Index          Normal control   Adenomyosis   Endometrial polyps   Endometrial adenocarcinoma                           
  -------------- ---------------- ------------- -------------------- ---------------------------- ------- ------- ------- -------
  p53 mRNA\      0.874            0.005         0.751                0.032                        0.727   0.041   0.727   0.041
  MDM2 mRNA                                                                                                               

  p53 protein\   0.892            0.003         0.718                0.045                        0.921   0.002   0.723   0.042
  MDM2 protein                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------

###### 

Expression of p53 and MDM2 in samples with different stages measured by immmunohistochemical staining.

  Staging   N   p53   MDM2                                                                       
  --------- --- ----- ------ ----------------------------------------------------------- --- --- -----------------------------------------------------------
  I         6   4     2      33.33                                                       4   2   33.33
  II        7   3     4      57.14[\*](#tfn2-medscimonit-22-4786){ref-type="table-fn"}   1   6   95.71[\*](#tfn2-medscimonit-22-4786){ref-type="table-fn"}
  III       6   0     6      100[\*](#tfn2-medscimonit-22-4786){ref-type="table-fn"}     0   6   100[\*](#tfn2-medscimonit-22-4786){ref-type="table-fn"}

*P*\<0.05.
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